Seer Inc

Seer's mission is to eliminate the technological barriers that have historically limited proteomics, aspiring to catalyze discovery at a pace seen in genomics. Its core achievement is the Proteograph platform, which uses nanoparticle enrichment and mass spectrometry to provide an unbiased, deep, and scalable view of the proteome from minimal sample input. The company's strategy is to commercialize this platform through instrument/consumable sales and its Technology Access Center (STAC) service arm, targeting academic, biopharma, and diagnostic customers. Having gone public in 2020, Seer is now focused on driving platform adoption and building a foundational catalog of proteomic data to establish a new standard in life sciences research tools.

The Proteograph Product Suite uses engineered nanoparticles with diverse surface chemistries to enrich and fractionate proteins from biological samples, enabling unbiased, deep, and scalable proteomic analysis when coupled with mass spectrometry.

Seer competes with traditional mass spectrometry workflows (Thermo Fisher, Bruker) and high-throughput affinity-based platforms (Olink, SomaLogic). Its key differentiation is offering unbiased discovery potential at scale, bridging the gap between the depth of traditional MS and the throughput of array-based methods.